Skip to main content
TipRanks
Go Ultimate75% OFF

Armen Shanafelt Insider Profile

11 Followers

Armen Shanafelt, Director at Spyre Therapeutics, holds 150.00K shares in Spyre Therapeutics (Ticker: SYRE), holds ― shares in Protagonist Therapeutics (Ticker: PTGX), holds ― shares in Rein Therapeutics (Ticker: RNTX). Most recently, Armen Shanafelt Bought ― shares of Spyre Therapeutics on Dec 13, 2021 for an estimated value of $548.72K.

Armen Shanafelt's Trading History

SYRE
Spyre Therapeutics
Dec 13, 2021DirectorInformative Buy548.72K$14.91M
SURF
Surface Oncology
Apr 23, 2018―Uninformative Buy―$3.69M
RNTX
Rein Therapeutics
―Director――
PTGX
Protagonist Therapeutics
―Director, Ten Percent Owner――

You May Also Like

Armen Shanafelt insider profile FAQ

What is the percentage of profitable transactions made by Armen Shanafelt?
The percentage of profitable transactions made by Armen Shanafelt is 0%.
What is the average return per transaction made by Armen Shanafelt?
The average return per transaction made by Armen Shanafelt is -78.80%.
What stocks does Armen Shanafelt hold?
Armen Shanafelt holds: SYRE, PTGX, RNTX, SURF stocks.
What was Armen Shanafelt’s latest transaction?
Armen Shanafelt’s latest transaction was an Informative Buy of $548.72K.
What was Armen Shanafelt's most profitable transaction?
Armen Shanafelt’s most profitable transaction was an Informative Buy of SURF stock on April 23, 2018. The return on the trade was -68.10%.
What is Armen Shanafelt's role in Spyre Therapeutics?
Armen Shanafelt's role in Spyre Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.